HIV Infections
Conditions
Keywords
epidemiology
Brief summary
HIV infection requires lifelong continuous antiretroviral (ARV) treatment. The efficacy of current ARV treatments makes it possible to propose strategies for reducing the cumulative exposure to ARVs, side effects and costs. And so improve the quality of life of people living with HIV (PLHIV). However, in the real world, less regular adherence to treatment, more heavily pre-treated patients and resistance to treatment make these dual therapies prescribed beyond the strict framework of clinical trials. This can lead to undesirable side effects. From the perspective of personalized medicine, it seems to be important to determine which patients are receiving dual ARV therapy, and which patients remain on it for a long time. Identifying prognostic factors would enable us to adapt therapeutic management.
Interventions
OTHERdual therapy
The evaluation will focus on the retention of patients living with hiv on dual antiretroviral therapy.
Sponsors
Tourcoing Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* hiv patient * viral load \< 50copies/ml * patient treated with dual therapy * patients with hospital follow-up between 2011 and 2023
Exclusion criteria
* adults under legal protection * underage
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| therapeutic switch | 5 years | Proportion of patients switching from dual to triple therapy |
Countries
France
Outcome results
None listed